Tumor Delineation with SUV 2.5 for 18F-FDG PET in Lung Cancer
Tumor Delineation in Lung Cancer
Keywords:
PET, tumor delineation, treatment planning, lung cancerAbstract
The most common cause of cancer death is lung cancer. Recently, 18F-FDG PET/CT has been an important tool of target volume delineation in radiotherapy treatment planning. The objective of this retrospective study was to assess target volume delineation obtained by SUV 2.5 for 18F-FDG PET images of 18 lung cancer patients, admitted from December 2011 to December 2016. Primary tumor volumes obtained by SUV 2.5 were delineated. Tumor volume, equivalent sphere diameter and disc similarity coefficient were calculated. Values of median, mean and standard deviation were presented. All values were compared with manually delineation of radiation oncologist, by using Wilcoxon signed rank test and paired t test, correlation reported by Pearson correlation coefficient (r), with statistically significant at 0.05 level. Results showed that median of tumor volume obtained by SUV 2.5 was 41.21 cubic centimeter that was smaller than manually delineation, which was 51.59 cubic centimeter (p = 0.002). Good correlation was presented (r = 0.929). In addition, median of equivalent sphere diameter obtained by SUV 2.5 and manually delineation were 4.29 and 4.83 centimeter, respectively (p = 0.006). Good correlation was showed (r = 0.952). Median of disc similarity coefficient was 0.57. In conclusion, tumor volume and equivalent sphere diameter of SUV 2.5 delineation are small than manually delineation with high correlation.
References
2. Guerra JL, Gladish G, Komaki R, Gomez D, Zhuang Y, Liao Z. Large decreases in standardized uptake values after definitive radiation are associated with better survival of patients with locally advanced non-small cell lung cancer. J Nucl Med 2012;53(1):225-33.
3. Wu Y, Li P, Zhang H, Shi Y, Wu H, Zhang J, et al. Diagnostic value of fluorine 18 fluorodeoxyglucose positron emission tomography/computed tomography for the detection of metastases in non-small cell lung cancer patients. Int J Cancer2013;
132(2):37-47.
4. Berberoglu K. Use of positron tomography/computed tomography in radiation treatment planning for lung cancer. Mol Imaging Radionucl Ther 2016;25(2):50-62.
5. Yin LJ, Yu XB, Ren YG, Gu GH, Ding TG, Lu Z. Utilization of PETCT in target volume delineation for three-dimensional conformal radiotherapy in patients with non-small cell lung cancer and atelectasis. Multidiscip Respir Med 2013;8(1):21-8.
6. Konert T, Vogel W, MacManus MP, Nestle U, Belderbos J, Gregoire V, et al. PET/CT imaging for target volume delineation in curative intent radiotherapy of non-small cell lung cancer: IAEA Consensus Report 2014. Radiother Oncol 2015;116(1):27-34.
7. Duhaylongsod FG, Lowe VJ, Patz EF, Vaughn AL, Coleman RE, Wolfe WG. Detection of primary and recurrent lung cancer by means of F-18 fluorodeoxyglucose positron emission tomography (FDGPET). J Thorac Cardiovasc Surg 1995;110(1):130-9.
8. De Ruysscher D, Nestle U, Jeraj R, Macmanus M. PET scans in radiotherapy planning of lung cancer. Lung Cancer 2012;75(2):141-5.
9. Gaede S, Olsthoorn J, Louie AV, Palma D, Yu E, Yaremko B, et al. An evaluation of an automated 4D-CT contour propagation tool to define an internal gross tumour volume for lung cancer radiotherapy. Radiother Oncol 2011;101(1):322-8.
10. Ciernik IF, Dizendorf E, Baumert BG, Reiner B, Burger C, Davis JB,et al. Radiation treatment planning with an integrated positron emission and computer tomography (PET/CT): A feasibility study. Int J Radiat Oncol Biol Phys 2003;57(3):853-63.
11. Vees H, Casanova N, Zilli T, Imperiano H, Ratib O, Popowski Y, et al. Impact of 18 F-FDG PET/CT on target volume delineation in recurrent or residual gynaecologic carcinoma. Radiat Oncol 2012;7(1):176-83.
12. Cheebsumon P, Boellaard R, de Ruysscher D, van Elmpt W, Baardwijk A, Yaqub M, et al. Assessment of tumour size in PET/CT lung cancer studies: PET- and CT-based methods compared to pathology. EJNMMI
Res 2012;2(1):56. doi: 10.1186/219-219X-2-56.
13. Yu HM, Liu YF, Hou M, Liu J, Li XN, Yu JM. Evaluation of gross tumor size using CT, 18F-FDG PET, integrated18F-FDG PET/CT and pathological analysis in non-small cell lung cancer. Eur J Radiol 2009;72(1):104-13.
14. Keyes JW. SUV: Standard uptake or silly useless value? J Nucl Med 1995;36:1836-9.
15. Chi A, Nguyen NP. The utility of positron emission tomography in the treatment planning of image-guided radiotherapy for non-small cell lung cancer. Front Oncol 2014;4(1):273-80.
